Skip to content

The effect of Boswellia resin extract on treatment of patients with Parkinson's disease

Boswellia resin extract effect on plasma levels of inflammatory cytokines in patients with Parkinson's disease

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20170315033086N4
Enrollment
50
Registered
2019-04-12
Start date
2017-06-22
Completion date
Unknown
Last updated
2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson disease. Parkinson disease

Interventions

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 85 Years

Inclusion criteria

Inclusion criteria: In accordance to UPDRS, only pationts in mild and moderate stage will be recruited No background of parkinson desease in patient’s family. It must be recorded in the primary questionnaire. The substance consumed in this research make no conflict with prescribed medicines by the physician, and all the patients recruited in this study will receive the same combination of medicines. BMI between 18 to 25, this parameter is determined by researcher and physician. No background of peptic ulcer, any surgery of digesting system, or haemorrhage of digesting system Age between 55 and 85 No severe heart or vascular disease No kidney or liver disorder

Exclusion criteria

Exclusion criteria: Acute or severe infectious disease (viral, bacterial) during research

Design outcomes

Primary

MeasureTime frame
Pro- and anti-inflammatory factors. Timepoint: At the recruitment day and after intervention. Method of measurement: ELISA assay kit.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahid Beheshti University of Medical Sciences

Bahram Yaghmayi

msp@sbmu.ac.ir+98 21 2387 2570

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026